SCHEMBL24511489

SCHEMBL24511489

CN(C(=O)N1CCC(O)C1)C1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.41
ALDH1A1 P00352 3/20 0.41
PKM P14618 1/20 0.41
LIPE Q05469 1/20 0.40
SIGMAR1 Q99720 1/20 0.38
HSD11B1 P28845 1/20 0.37
HSD11B2 P80365 1/20 0.37
FAAH O00519 1/20 0.37
PHGDH O43175 1/20 0.37
MGLL Q99685 1/20 0.37
MCHR1 Q99705 3/20 0.36
USP30 Q70CQ3 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
ATM Q13315 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24511675 1.00 DPP4 (0.41) DPP4ALDH1A1PKMLIPESIGMAR1
SCHEMBL24517987 1.00 DPP4 (0.41) DPP4ALDH1A1PKMLIPESIGMAR1
SCHEMBL30937010 0.91 DPP4 (0.44) DPP4MCHR1USP30DPP8
SCHEMBL30937050 0.91 DPP4 (0.44) DPP4MCHR1USP30DPP8
SCHEMBL24511505 0.85 DPP4 (0.40) DPP4ALDH1A1MCHR1DPP8
SCHEMBL30937160 0.80 MEN1 (0.39) DPP4LIPEHSD11B1HSD11B2MCHR1
SCHEMBL28019652 0.80 LIPE (0.44) ALDH1A1PKMLIPEHSD11B1HSD11B2
SCHEMBL24518383 0.80 LIPE (0.44) ALDH1A1PKMLIPEHSD11B1HSD11B2
SCHEMBL15551380 0.80 LIPE (0.44) ALDH1A1PKMLIPEHSD11B1HSD11B2
SCHEMBL30937055 0.78 DPP4 (0.47) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022122876-A1 N-(IMIDAZO[1,2-B]PYRIDAZIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE AND N-(PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-1-CYCLOHEXYL-2H-INDAZOLE-5-CARBOXAMIDE DERIVATIVES AS IRAK4 INHIBITORS FOR THE TREATMENT OF ASTHMA ASTRAZENECA AB (SE) 2022-06-16 WO disclosed
US-20220185817-A1 IRAK4 INHIBITORS ASTRAZENECA AB (SE) 2022-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185817-A1 IRAK4 INHIBITORS IRAK4, IRAK2, IRAK1 DPP4 148/4885ALDH1A1 2671/4885PKM 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.